Hims & Hers Health is trading 6.92% down at €25.54 after its August 10, 2026 second-quarter report showed a $0.37 GAAP loss per share, versus a $0.05 estimate.
- Revenue reached $753.2 million, while full-year revenue guidance increased to $3.2 billion.
- The loss was attributed to legal and acquisition costs; investors also focused on restructuring charges and margin pressure.
- The decline followed the earnings release rather than broad market weakness.